Shi Hai-Yun, Pan Chen, Ma Ting-Ting, Chen Yan-Lei, Yan Wei-Jun, Liu Jian-Guo, Cao Meng-Da, Huang Hong-Dong, Wang De-Yun, Wang Xue-Yan, Wei Ji-Fu
Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Front Pharmacol. 2020 Mar 18;11:305. doi: 10.3389/fphar.2020.00305. eCollection 2020.
Subcutaneous immunotherapy is the only treatment that improves the natural progression of allergic rhinitis and maintains long-term outcomes after discontinuation of the drug. Metabolomics is increasingly applied in the study of allergic diseases, including allergic rhinitis. However, little is known about the discovery of metabolites that can evaluate clinical efficacy and possible mechanisms of pollen subcutaneous immunotherapy. Thirty-three patients with pollen allergic rhinitis significantly improved after 1-year subcutaneous immunotherapy treatment, while ten patients were ineffective. Pre- and post-treatment serum samples from these patients were analyzed by metabolomics based on the combined detection of liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry. As a result, L-Tyrosine can be a potential biomarker because of its opposite trend in effective patients and ineffective patients. And mechanism of immunotherapy may be closely related to NO and nitric oxide synthase. The discovery of potential biomarkers and metabolic pathways has contributed to the in-depth study of mechanisms of subcutaneous immunotherapy treatment of pollen allergic rhinitis.
皮下免疫疗法是唯一一种能够改善过敏性鼻炎自然病程并在停药后维持长期疗效的治疗方法。代谢组学越来越多地应用于包括过敏性鼻炎在内的过敏性疾病研究。然而，关于能够评估花粉皮下免疫疗法临床疗效及可能机制的代谢物发现却知之甚少。33例花粉过敏性鼻炎患者经1年皮下免疫疗法治疗后症状显著改善，而10例患者治疗无效。基于液相色谱-质谱联用和气相色谱-质谱联用的联合检测，采用代谢组学方法对这些患者治疗前后的血清样本进行分析。结果显示，L-酪氨酸可能是一种潜在生物标志物，因为其在有效患者和无效患者中的变化趋势相反。并且免疫疗法的机制可能与一氧化氮（NO）和一氧化氮合酶密切相关。潜在生物标志物和代谢途径的发现有助于深入研究皮下免疫疗法治疗花粉过敏性鼻炎的机制。
